The Psychedelics as Medicine Report (I)

The use of psychedelics as medicine has opened up a new industry growing exponentially at a rapid pace. 

_PSYCH tracks key psychedelic players, innovations and milestones, providing trustworthy insights to help investors cut through the noise and identify real opportunities. 

_PSYCH provides a coercive perspective on the commercial impact of changing global regulations, drug discovery and corporate activity. We connect operators to a qualified audience with access to capital, ready to support industry growth and help them achieve their goals. 

_PSYCH unlocks the commercial potential of psychedelics.

The psychedelic substances profiled in this report are either naturally occurring, such as psilocybin, ayahuasca and ibogaine; or, like LSD and MDMA, are (semi-)synthetically manufactured in a laboratory setting. Naturally occurring psychedelics, such as psilocybin, can also be synthetically manufactured. 

Novel psychedelic compounds can also be synthesised based on existing substances.

 If the United States FDA awards a substance/ treatment Breakthrough Therapy designation (BTD), this means the FDA will expedite the substance’s development and review process because clinical evidence has shown that it may offer a substantial improvement over existing therapies. BTD has been given to COMPASS Pathways and Usona Institute to develop psilocybin to treat depression, to the Multidisciplinary Association for Psychedelic Studies (MAPS) which is developing MDMA to treat post-traumatic stress disorder (PTSD), and to Janssen & Janssen for the treatment of TRD with Spravato.

•  Serotonin (5-HT)
•  Indole alkaloid
•  Psychedelics
•  Psilocybin (‘magic’ mushrooms)
•  Ibogaine
•  Mescaline (peyote)
•  Ayahuasca
•  DMT
•  5-MeO-DMT
•  LSD
•  MDMA
•  Ketamine
•  Esketamine
• Salvia divinorum